Search

【目的】探讨妊娠期糖尿病（GDM）患者孕期血脂水平对产后糖脂代谢的影响。【方法】随访确诊为GDM并完成产后复查妇女416例，根据孕期血脂分为孕期血脂正常组（n=82）和孕期血脂异常组（n=334），收集产后4-12周一般人口学资料，检测OGTT血糖、胰岛素水平以及血脂水平，比较两组产后糖脂代谢参数差异。【结果】GDM妇女产后早期糖代谢异常率为38.5%，血脂异常发生率为34.4%；孕期血脂异常组产后总胆固醇、甘油三酯以及低密度脂蛋白胆固醇水平均明显高于孕期血脂正常组，其中孕期高TC血症和高LDL-c血症患者产后血脂异常比例显著升高。相关分析显示孕期TGHDL-c与产后空腹血糖和胰岛素抵抗指数（HOMA-IR）分别呈正相关及负相关。【结论】GDM患者孕期血脂异常与产后早期糖脂代谢紊乱相关。

【目的】探讨那格列奈对初诊2型糖尿病患者空腹游离脂肪酸的影响。【方法】42例从未进行降糖及降脂药物治疗的初诊2型糖尿病患者，随机分为那格列奈组及瑞格列奈组各21例，测定空腹游离脂肪酸（FFA）及空腹血糖（FPG）、标准餐后2h血糖（2hPG）、血脂谱，次日行静脉葡萄糖胰岛素释放试验（IVG-IRT）后，分组给予那格列奈60～90mg或瑞格列奈0．5～1．0mg，双盲治疗12周后，重复前述检查。【结果】37例完成试验，那格列奈组（18例）空腹FFA从（0．47±0．18）mmol／L下降到（0．36±0．16）mmol／L，平均下降（0．11±0．21）mmol／L（P〈0．05），瑞格列奈组（19例）空腹FFA无显著变化，那格列奈组比瑞格列奈组空腹FFA降低有明显差异。两组患者血脂谱无明显变化，治疗后FPG、2hPG、HbAlc及胰岛素抵抗指数较治疗前均有明显下降（R0．05）．胰岛B细胞功能指数（HOMA-B）、IVG-IRT 10min内急性胰岛素反应（AIR）均有明显增加（P〈0．05），组间比较无明显差异（P〉0．05）。【结论】那格列奈有降低空腹游离脂肪酸的倾向，其机制可能独立于改善胰岛功能之外。

【目的】探讨细胞毒性T淋巴细胞相关抗原-4(cytotoxic T lymphocyte associated antigen 4)基因第一外显子A／G(49)多态性与中国南方汉族人群Graves′病的关系。【方法】用PCR-RFLP确定CTLA-4基因第1外显子49位点基因型，分析广东地区汉族人Graves′病患者(GD组)120例及123名正常人(对照组)CTLA-4基因多态性。并把GD患者按性别、家族史、TRAb、突眼等分别分两亚组后分析CTLA-4基因第1外显子A49G位点基因型及等位基因的频率。【结果】CTLA-4基因第1外显子49位点G等位基因频率在GD组为0.704，对照组为0.679，A等位基因频率在GD组为0.296，对照组为0.321，基因型频率GG在GD组为0.483，对照组为0.447，AA在GD组为0.089，对照组为0.075，二组间均无统计学差异，P值均＞0.05。在GD组，按性别、家族史、TRAb及突眼进行分亚组后分析，CTLA-4基因A49G位点的基因型、等位基因频率也没有表现出差异(P值均＞0.05)。【结论】CTLA-4基因第一外显子A／G(49)多态性可能不是中国南方汉族人Graves′病的主要易感因素。

【目的】观察左旋肉碱对超重2 型糖尿病病人体脂、血脂和血糖调节等作用。【方法】随机双盲对照以50 例2 型 糖尿病病人随机进入左旋肉碱治疗组(用药组)或安慰剂组(对照组), 左旋肉碱用量为每日3 g , 连服3 个月。【结果】 用药组 病人总体脂肪百分数从治疗前35.4%±7.1 %降至32.9%±6.9%(P

In the early stages of type 2 diabetes， inducing remission of hyperglycemia has become a global hotspot in the field of diabetes management. In recent years， scholars from both domestic and international communities have established several remission intervention methods， including short-term intensive insulin therapy， life- style intervention， and metabolic surgery. They have also proposed theories such as beta-cell dedifferentiation and liver-pancreas" twin cycle" hypothesis， which have accelerated the growth of clinical and research information in this field. This review summarizes the clinical evidence， basic mechanisms， applicable populations， and exacutive principle points in the field of diabetes remission， with the aim of deepening the understanding of clinical practitio- ners about diabetes remission and laying the foundation for better practice and research in related fields. [ABSTRACT FROM AUTHOR]

Copyright of Power Generation Technology is the property of Power Generation Technology Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Chinese Journal of Osteoporosis is the property of Chinese Journal of Osteoporosis and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

短期胰岛素强化治疗是强化血糖控制的重要方法之一, 适用于糖化血红蛋白≥9.0%或 空腹血糖≥11.1 mmol/L, 或伴有明显高血糖症状的新诊断2型糖尿病患者, 以及已经使用多种口服降 糖药联合治疗3个月以上血糖仍明显升高（如糖化血红蛋白≥9.0%）, 或使用胰岛素治疗并经过充分的 剂量调整血糖仍未达标的2型糖尿病患者。实施短期胰岛素强化治疗有助于快速减轻高糖毒性, 改 善患者预后。从事相关内容研究的内分泌专家组成了《2型糖尿病短期胰岛素强化治疗专家共识》编 写委员会, 以2017年《2型糖尿病短期胰岛素强化治疗临床专家指导意见》为基础, 结合最新的循证医 学证据和研究新进展, 形成了《2型糖尿病短期胰岛素强化治疗专家共识（2021年版）》。内容涵盖短 期胰岛素强化治疗的定义和临床获益、治疗的适用人群、血糖控制目标和治疗方案、短期胰岛素强化 治疗的后续血糖管理、2型糖尿病特殊人群的短期胰岛素治疗注意事项、低血糖发生的原因及对策 等, 并给出了2型糖尿病患者的短期胰岛素强化治疗路径, 以期指导临床治疗, 使患者获益。. [ABSTRACT FROM AUTHOR]

2型糖尿病（T2DM）在早期具有一定的可逆性。短期胰岛素强化治疗可显著改善胰岛β 细胞功能和胰岛素敏感性，是一种逆转T2DM的有效手段。为了更好地指导短期胰岛素强化治疗逆 转T2DM的临床实践，专家组特通过系统整理现有的临床证据，结合实践经验，形成了本共识推荐意 见。本共识中给出了糖尿病缓解、高血糖逆转的定义，推荐对符合条件的新诊断T2DM患者或原治疗 方案无法使血糖达标的T2DM患者采用短期胰岛素强化逆转治疗;短期胰岛素强化逆转治疗期间，应 以血糖正常化为目标;强化治疗的疗程为血糖达标后至少2周;强化治疗后应结合现有的临床证据进 行疗效预判，进而制定个体化后续管理方案。. [ABSTRACT FROM AUTHOR]

Copyright of Chinese Journal of Diabetes Mellitus is the property of Chinese Journal of Diabetes Mellitus and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Chinese Journal of Diabetes Mellitus is the property of Chinese Journal of Diabetes Mellitus and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Chinese Journal of Diabetes Mellitus is the property of Chinese Journal of Diabetes Mellitus and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

2型糖尿病及其并发症的流行给我国的疾病管理系统造成了很大负担。传统的升阶治 疗管理模式所固有的滞后性缺陷，影响了患者从治疗中获得最大收益。近年来对该领域的新进展促 使我们对2型糖尿病防治策略进行重新考量。2型糖尿病的防治应当坚持以降低心血管并发症为导 向，重视早期病情的可逆性；在策略上应当重视早期综合风险因素的联合达标，切实降低心血管剩余 风险，同时须把握早期强化治疗实现病情逆转的时间窗，从根本上延缓疾病和并发症的进展；在具体 手段上应当结合最新的临床成果，结合实际情况选用具有大血管和微血管获益的治疗药物，以更主动 和积极的姿态，实现《健康中国2030规划纲要》中糖尿病综合防治目标. [ABSTRACT FROM AUTHOR]

Copyright of Chinese Journal of Diabetes Mellitus is the property of Chinese Journal of Diabetes Mellitus and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

持续葡萄糖监测在临床中应用越来越普及，近年来葡萄糖目标范围内时间（time in range，TIR）越来越受到关注，其可更全面反映患者的血糖控制水平，是糖化血红蛋白的重要补充，并 与糖尿病视网膜病变和微量白蛋白尿之间存在显著相关性，为规范临床上TIR的应用，糖尿病先进技 术与治疗大会就TIR的临床应用形成了国际共识，对TIR测定方法、技术要求、不同患者目标设定作 出了具体推荐，TIR将成为血糖控制及糖尿病综合管理的重要指标之一. [ABSTRACT FROM AUTHOR]

Copyright of Chinese Journal of Diabetes Mellitus is the property of Chinese Journal of Diabetes Mellitus and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)